ABBV vs GS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
The Goldman Sachs Group, Inc. · Financial Services
$907.80
-3.1% upside to fair value
Low Conviction
Grade C+
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GS |
| Current Price |
$208.05 |
$907.80 |
| Fair Value Estimate |
$217.50 |
$880.00 |
| Upside to Fair Value |
+4.5%
|
-3.1%
|
| Market Cap |
$367.9B |
$269.4B |
| Forward P/E |
14.9x
|
15.6x
|
| EV / EBITDA |
16.7x
|
29.7x
|
| Price / Sales |
6.1x
|
2.1x
|
| Price / FCF |
20.9x
|
—
|
| Revenue Growth YoY |
+8.6%
|
+9.0%
|
| Gross Margin |
83.7%
|
47.5%
|
| Operating Margin |
34.7%
|
17.5%
|
| Return on Equity |
-129.24%
|
13.8%
|
| Dividend Yield |
3.2% |
1.71% |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Goldman Sachs remains the premier global investment bank with dominant franchises in M&A advisory, equities trading, and asset management. FY2025 delivered $58.3B net revenues, 15% ROE, and $51.32 diluted EPS, powered by record equities trading and a resurgent IB pipeline. The stock has pulled back 8% from January highs near $985 but still trades at 2.27x book value, well above the 5-year median …
Accumulation Zones
| Metric |
ABBV |
GS |
| Zone Low |
$163.13 |
$600.00 |
| Zone High |
$184.88 |
$680.00 |
| In Buy Zone? |
No
|
No
|